Bioventus (US:BVS)2024-03-12 15:02Financial Performance - Q4 2023 - Revenue increased by 8% to $135 million compared to the prior year quarter[26] - Pain Treatments revenue increased 23% compared to prior year[27] - Surgical Solutions revenue grew 12%[27] - Adjusted EBITDA increased by $5 million to $22 million compared to the prior year quarter[26] - Adjusted gross margin increased 20 basis points to 71.4%[30, 31] Financial Position - Debt outstanding is $395 million[35] - Cash balance at the end of the quarter is $37 million[50] 2024 Financial Guidance - Expect net sales to be in the range of $520 million to $535 million[51] - Expect adjusted EBITDA to be in the range of $89 million to $94 million[37] Strategic Initiatives - Accelerating revenue growth, especially in Ultrasonics with double-digit growth expected[7] - Prioritizing funding initiatives and re-allocating resources to maximize return[7] - Improving operational efficiency and reducing expenses related to integrations and debt restructuring[18] - Organic revenue growth increased 14% compared to the prior year quarter when adjusting for the divestiture of Wound Business[21]